Australian Clinical Labs Ltd (AU:ACL) has released an update.
UBS Group AG and its related entities have become substantial holders in Australian Clinical Labs Limited, with a collective voting power of 7.74% as of September 11, 2024. This stake comprises over 15 million ordinary shares, controlled through various means including stock borrowing and lending activities, as well as fund management. The involved UBS entities are registered with several different nominee companies.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
